Literature DB >> 875083

Indications for thoracotomy following penetrating thoracic injury.

R Siemens, H C Polk, L A Gray, R L Fulton.   

Abstract

The treatment of penetrating thoracic injuries has been reviewed in both civilian and military series. Although most surgeons agree that closed that closed thoracostomy drainage is the initial treatment of choice, the timing of early thoracotomy and perhaps cardiorrhaphy upon patients with penetrating thoracic injuries remains controversial. The purpose of this study was to determine which patients will require immediate thoractomy or cardiorrhaphy following penetrating chest injury. Over a two-year period 190 patients with penetrating thoracic injuries were treated. Of 53 patients who required immediate thoracotomy, 31 suffered cardiac wounds. Seventy-nine patients required laparotomy for associated intra-abdominal injuries. The mortality rate was related to exsanguinating hemorrhage or postoperative intra-abdominal sepsis. Cardiopulmonary complications were rare in the absence of intra-abdominal sepsis and could not be attributed to the thoracic injury or thoracotomy. Indications for immediate cardiorrhaphy or thoracotomy are: 1) location of the entrance wound (70% in upper mediastinum); 2) blood pressure on admission less than 90; 3) initial thoracostomy blood loss greater than 800 cc; 4) radiographic evidence of retained hemothorax; and/or 5) clinical evidence of pericardial tamponade.

Entities:  

Mesh:

Year:  1977        PMID: 875083     DOI: 10.1097/00005373-197707000-00002

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  3 in total

1.  Traumatic pericardial tamponade: relearning old lessons.

Authors:  R Crawford; H Kasem; A Bleetmen
Journal:  J Accid Emerg Med       Date:  1997-07

2.  Penetrating cardiac injuries.

Authors:  D P Taggart; I J Reece
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-27

3.  Principles for the management of penetrating cardiac wounds.

Authors:  J Evans; L A Gray; A Rayner; R L Fulton
Journal:  Ann Surg       Date:  1979-06       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.